Business
Boundless Bio is a clinical-stage oncology company developing therapies directed at extrachromosomal DNA, or ecDNA, in oncogene-amplified tumors.
Boundless Bio is a clinical-stage ecDNA oncology company with no revenue, lower burn, eroded equity, and a 2025 restructuring.
The read at a glance✓ Audited against SEC data
- Business mix — ecDNA oncology therapeuticsNote
- Revenue — No revenueWatch
- FCF — -$47.2MWatch
- Loss — Net loss narrowed 11.0%OK
- Equity — $98.7M, -34.5%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Forensic screens unavailableNote
Leadership changes
From Boundless Bio, Inc.'s own filings, the day they're filed.
- Klaus Wagner · Chief Medical Officer · departureeff. 2024-12-29
- Jami Rubin · Chief Financial Officer · departureeff. 2024-10-11
- David Hinkle · President · appointment
Latest filings
- 8-K · Company announcement2026-08-28
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-06-17
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Boundless Bio, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.